Two new biological drugs (vedolizumab and ustekinumab) and one small molecule
(tofacitinib) have been recently approved for the treatment of inflammatory bowel disease …

2. Methods This document represents the third version of the European Consensus on
reproduction in IBD. The development of this Consensus included the formulation of …

Introduction: The peak age of diagnosis of inflammatory bowel disease (IBD) occurs during
childbearing years, therefore management of IBD during pregnancy is a frequent …

An increasing and early-onset use of immunosuppressives and biologics has become more
frequently seen among patients with inflammatory bowel diseases (IBD) and rheumatic …

The management of inflammatory bowel disease requires continuous medical therapy to
achieve and maintain disease control. Thus, women can be exposed to different drugs …

Exposure in utero and elimination of Adalimumab and Infliximab in neonates (the ERA study): a
prospective cohort study Page 1 1 Tofacitinib concentrations in plasma and breast milk of a …

Abstract Background and Aims Vedolizumab is an IgG1 anti-α4β7 integrin antibody
approved for the treatment of inflammatory bowel diseases [IBD], but without clear safety …

Background Little is known about the consequences of intrauterine exposure to, and the
post‐natal clearance of, vedolizumab. Aims To investigate the levels of vedolizumab in …

Inflammatory bowel disease (IBD) affects patients during their peak reproductive years. This
raises important questions, in both patients and healthcare providers, regarding conception …

Objective To review currently available data on the transfer of monoclonal antibodies (mAbs)
in the breastmilk of women receiving treatment for neurologic and non-neurologic diseases …